Ginkgo Bioworks: CFO Coen Steven P. sold 766 shares

What happened

• The filing says Coen Steven P., chief financial officer, exercised or converted derivatives for 1,174 shares and 312 shares on Oct 16, 2026 (total 1,486 shares) and sold 766 shares at $10.14 on Oct 19, 2026 for $7,770.
• The filing lists both acquired and disposed entries for the Oct 16 transactions (derivative exercise/conversion).

Key details

• Transaction dates and prices: Oct 16, 2026 — exercise/conversion of derivatives for 1,174 and 312 shares (code M, no price listed); Oct 19, 2026 — open market sale of 766 shares at $10.14 for $7,770.
• Shares owned after the transaction: not stated in the filing.
• Relevant footnotes from the filing:
  • F1: each restricted stock unit (RSU) represents a contingent right to one share of class A common stock.
  • F2: the filing says shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock and/or RSUs (sell-to-cover).
  • F3/F4: the RSUs vest on schedules beginning May 1, 2024 with monthly installments (details in the filing).
• Filing date and reporting period: filed Oct 21, 2026; period of report Oct 16, 2026.

Why it may matter

• The filing says the reporting person exercised or converted derivative RSU awards and a portion of shares was sold (sell-to-cover) to satisfy tax withholding.
• The filing does not state whether the exercises were part of a cashless exercise beyond the sell-to-cover entry.
• A filing does not show why the insider traded or why the company acted.